ColonScan
A simple to use, accurate and cost-effective blood test for large-scale colon cancer screening
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0ColonScan project word cloud
Explore the words cloud of the ColonScan project. It provides you a very rough idea of what is the project "ColonScan" about.
Project "ColonScan" data sheet
The following table provides information about the project.
| Coordinator |
UNIVERSAL DIAGNOSTICS SL
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Project website | http://www.universaldx.com |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-05-01 to 2018-09-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | UNIVERSAL DIAGNOSTICS SL | ES (SEVILLA) | coordinator | 50˙000.00 |
Map
Project objective
Universal Diagnostics (UDX) is a biomedicine start-up focused on early detection of cancer using leading-edge technologies. Our mission is to make cancer a curable disease by detecting it early through an accurate, simple to use, and cost-effective diagnostic kit. During the last 5 years, UDX has been developing a mass spectrometry (MS) based metabolic analysis that allows very cost-effective and accurate detection of metabolic markers in blood, for early detection of different types of cancer. The first product of the company (the one this proposal is all about) is ColonScan: A simple, noninvasive, accurate (AUC 92%) and inexpensive, blood-based screening test to detect colorectal cancer (CRC) and adenomas (precancerous stages), allowing early detection and cancer prevention. ColonScan will be highly accurate, easily scalable worldwide, simple to use, non-invasive and inexpensive; ColonScan presents all characteristics and requirements to be adopted as CRC screening program for average risk population since, our technology can be included routinely in normal blood tests at annual or biannual medical check-ups. Moreover, the metabolomics platform developed in ColonScan project can be applied and upscaled to other types of cancer with no cost increase. CRC is the third most commonly diagnosed and leading cause of cancer death in the world, despite CRC is considered a completely preventable disease. All CRC guidelines recommends regularly (annual or biannual) screening of average risk population (50-85 years old). This represents a huge market opportunity, which according to our conservative estimations means a target population of 380 Million people and 12 Billion market opportunity. The ultimate objective of ColonScan Phase 1 project is to assess the feasibility of our business innovation project, under a commercial, technical and financial point of view to minimize any potential risk that might endanger our business plan.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COLONSCAN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "COLONSCAN" are provided by the European Opendata Portal: CORDIS opendata.